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Summary
Background Despite the heightened risk of serious inﬂ uenza during infancy, vaccination is not recommended in infants 
younger than 6 months. We aimed to assess the safety, immunogenicity, and eﬃ  cacy of maternal immunisation with 
trivalent inactivated inﬂ uenza vaccine for protection of infants against a ﬁ rst episode of laboratory-conﬁ rmed inﬂ uenza.
Methods We did this prospective, active-controlled, observer-blind, randomised phase 4 trial at six referral centres and 
community health centres in Bamako, Mali. Third-trimester pregnant women (≥28 weeks’ gestation) were randomly 
assigned (1:1), via a computer-generated, centre-speciﬁ c list with alternate block sizes of six or 12, to receive either 
trivalent inactivated inﬂ uenza vaccine or quadrivalent meningococcal vaccine. Study personnel administering vaccines 
were not masked to treatment allocation, but allocation was concealed from clinicians, laboratory personnel, and 
participants. Infants were visited weekly until age 6 months to detect inﬂ uenza-like illness; laboratory-conﬁ rmed 
inﬂ uenza diagnosed with RT-PCR. We assessed two coprimary objectives: vaccine eﬃ  cacy against laboratory-conﬁ rmed 
inﬂ uenza in infants born to women immunised any time prepartum (intention-to-treat population), and vaccine eﬃ  cacy 
in infants born to women immunised at least 14 days prepartum (per-protocol population). The primary outcome was 
the occurrence of a ﬁ rst case of laboratory-conﬁ rmed inﬂ uenza by age 6 months. This trial is registered with 
ClinicalTrials.gov, number NCT01430689.
Findings We did this trial from Sept 12, 2011, to Jan 28, 2014. Between Sept 12, 2011, and April 18, 2013, we randomly 
assigned 4193 women to receive trivalent inactivated inﬂ uenza vaccine (n=2108) or quadrivalent meningococcal vaccine 
(n=2085). There were 4105 livebirths; 1797 (87%) of 2064 infants in the trivalent inactivated inﬂ uenza vaccine group and 
1793 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6 months. We 
recorded 5279 inﬂ uenza-like illness episodes in 2789 (68%) infants, of which 131 (2%) episodes were laboratory-
conﬁ rmed inﬂ uenza. 129 (98%) cases of laboratory-conﬁ rmed inﬂ uenza were ﬁ rst episodes (n=77 in the quadrivalent 
meningococcal vaccine group vs n=52 in the trivalent inactivated inﬂ uenza vaccine group). In the intention-to-treat 
population, overall infant vaccine eﬃ  cacy was 33·1% (95% CI 3·7–53·9); in the per-protocol population, vaccine eﬃ  cacy 
was 37·3% (7·6–57·8). Vaccine eﬃ  cacy remained robust during the ﬁ rst 4 months of follow-up (67·9% [95% CI 
35·1–85·3] by intention to treat and 70·2% [35·7–87·6] by per protocol), before diminishing during the ﬁ fth month 
(57·3% [30·6–74·4] and 60·7 [33·8–77·5], respectively). Adverse event rates in women and infants were similar among 
groups. Pain at the injection site was more common in women given quadrivalent meningococcal vaccine than in those 
given trivalent inactivated inﬂ uenza vaccine (n=253 vs n=132; p<0·0001), although 354 [92%] reactions were mild. 
Obstetrical and non-obstetrical serious adverse events were reported in 60 (3%) women in the quadrivalent 
meningococcal vaccine group and 61 (3%) women in the trivalent inactivated inﬂ uenza vaccine group. Presumed 
neonatal infection was more common in infants in the trivalent inactivated inﬂ uenza vaccine group than in those in the 
quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0·02). No serious adverse events were related to vaccination.
Interpretation Vaccination of pregnant women with trivalent inactivated inﬂ uenza vaccine in Mali—a poorly resourced 
country with high infant mortality—was technically and logistically feasible and protected infants from laboratory-
conﬁ rmed inﬂ uenza for 4 months. With adequate ﬁ nancing to procure the vaccine, implementation will parallel the 
access to antenatal care and immunisation coverage of pregnant women with tetanus toxoid.
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Introduction 
Pregnant women and young infants are at increased risk 
of developing severe, complicated, and sometimes fatal 
inﬂ uenza infection;1–4 however, no inﬂ uenza vaccines are 
approved for infants younger than 6 months.5–7 Maternal 
immunisation against inﬂ uenza is a promising strategy 
to reduce disease in pregnant women and young infants.8,9 
Trials in Bangladesh10 and South Africa11 showed 
protection against laboratory-conﬁ rmed inﬂ uenza in 
infants born to mothers who received trivalent inactivated 
inﬂ uenza vaccine, but additional health beneﬁ ts in those 
infants (eg, higher birthweight and reduced likelihood of 
being small for gestational age) have been inconsistent.11,12 
Remaining questions include more precise determination 
of the duration of protection for infants that can accrue 
from maternal immunisation,8 and the technical and 
logistical feasibility and eﬀ ectiveness of implementation 
of programmes in resource-limited settings with high to 
moderate infant mortality rates.13
We aimed to address these questions in the course of a 
post-licensure clinical trial of the safety, immunogenicity, 
and eﬃ  cacy of maternal inﬂ uenza immunisation for 
prevention of inﬂ uenza in infants younger than 6 months 
in Mali, west Africa—one of the world’s least developed 
countries, with the world’s seventh highest infant 
mortality rate.14,15 Mali, nevertheless, maintains a vaunted 
Expanded Program on Immunization (EPI) that includes 
immunisation of pregnant women with tetanus toxoid 
and the introduction of ﬁ ve new EPI vaccines for infants 
since 2005.16–18 Introduction of additional vaccines for 
pregnant women, particularly trivalent inactivated 
inﬂ uenza vaccine, the composition of which changes 
annually, would be challenging, but would make use of an 
existing eﬀ ective vaccine delivery platform.
Methods
Study design and participants
We did this prospective, active-controlled, observer-blind, 
randomised phase 4 trial at six referral centres and 
community health centres in Bamako, Mali. In the year 
before starting the trial, inﬂ uenza activity occurred from 
September to April, with peaks in October and February.
Third-trimester pregnant women (≥28 weeks’ gestation 
based on last menstrual period, ultrasound, or uterine 
height) presenting to participating health centres for 
prenatal care were eligible for inclusion. Participants had 
to be able to understand and comply with planned study 
procedures, provide written informed consent before 
initiation of any study procedures, and intend to reside in 
the study area until their newborn infants were 6 months 
old. Participants could not be members of a household 
that already had a woman who was participating or had 
Research in context
Evidence before this study
Immunisation of pregnant women against inﬂ uenza has been 
common practice in industrialised nations since their vulnerability 
to severe disease and adverse outcomes was recognised. 
Nevertheless, this practice has not been adopted by low-income 
countries with constrained resources. When we undertook this 
trial, maternal immunisation as a strategy to prevent infant 
illness and avert associated morbidity and mortality was gaining 
traction. We searched PubMed between April 17, 1996, and 
March 8, 2016, for clinical trials with the terms “maternal 
inﬂ uenza vaccination” and “maternal inﬂ uenza immunization”. 
Our search yielded 36 publications. Two publications were of 
randomised clinical trials done in low-income and middle-income 
countries that measured the eﬃ  cacy of maternal inﬂ uenza 
vaccination in protection of infants. The ﬁ rst trial, done in 
Bangladesh, reported 63% eﬃ  cacy in the reduction of 
laboratory-conﬁ rmed inﬂ uenza in infants aged up to 24 weeks. 
Furthermore, infants born to women who received inﬂ uenza 
vaccine were less likely to be small for gestational age and had a 
higher mean birthweight than did those born to women in the 
control group. The next trial was done in South Africa and 
reported 48·8% eﬃ  cacy in infants aged up to 24 weeks; however, 
the other beneﬁ ts to infants were not shown.
Added value of this study
Our trial represents the largest evaluation so far of maternal 
inﬂ uenza vaccination as a strategy to prevent inﬂ uenza in the 
youngest infants. Additionally, it is the ﬁ rst such study to be 
completed in west Africa, speciﬁ cally Mali, one of the poorest 
countries in the world. Demonstrating the eﬃ  cacy of 
maternal inﬂ uenza vaccination in this setting is compelling. 
Moreover, establishing that eﬃ  cacy is highest in the ﬁ rst 
4 months of life (67·9%) is important as the duration of 
protection conferred through maternal vaccination and 
anticipated beneﬁ ts are assessed. Finally, the absence of an 
eﬀ ect on the incidence of low birthweight is consistent with 
ﬁ ndings shown in South Africa.
Implications of all the available evidence
Our study unequivocally demonstrates eﬃ  cacy of maternal 
inﬂ uenza vaccination against laboratory-conﬁ rmed inﬂ uenza in 
infants and mothers. Moreover, there was high acceptability and 
logistical feasibility. However, our trial and that done in South Africa 
did not corroborate the previously reported beneﬁ ts on neonatal 
outcomes. Moreover, because these trials were not designed to 
measure an eﬀ ect on severe, deadly disease, there remains a notable 
gap when assessing the cost-eﬀ ectiveness of this intervention. 
Although the success of maternal tetanus immunisation 
programmes suggests that implementation of inﬂ uenza 
vaccination would also be successful, the related cost would need to 
be justiﬁ ed by the gains of the beneﬁ ts aﬀ orded so that local policy 
makers and donors could invest their restricted funds. 
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participated in this study. Other exclusion criteria were a 
history of severe reactions following previous immuni-
sation with inﬂ uenza or meningococcal vaccines; 
Guillain–Barré syndrome; known allergy or hyper-
sensitivity to eggs, egg proteins, latex, diphtheria toxoid, 
or any other components of trivalent inactivated 
inﬂ uenza vaccine (Vaxigrip) and quadrivalent meningo-
coccal conjugate vaccine (Menactra); known chronic 
medical disorder that, in the judgment of the investigator, 
could compromise assessment of the study vaccine or 
put the participant at risk; known active infection with 
HIV, hepatitis B virus, or hepatitis C virus; complications 
with the ongoing pregnancy, including preterm labour 
(with cervical change), placental abruption, premature 
rupture of membranes, known major congenital 
anomaly, or pre-eclampsia; acute illness or an oral 
temperature greater than or equal to 37·8°C within 72 h 
of vaccination (resulted in a temporary delay of 
vaccination); receipt of any other vaccine, excluding 
tetanus toxoid, within 2 weeks (for inactivated vaccines) 
or 4 weeks (for live vaccines and meningococcal A 
conjugate vaccine) before vaccination in this study; 
receipt of immunoglobulins or any blood products 
within 30 days before administration of study vaccines; 
chronic administration of immuno suppressants or other 
immune-modifying drugs within 90 days before 
administration of study vaccines; or any disorder that, in 
the opinion of the investigator, might compromise the 
wellbeing of the participant or compliance with study 
procedures, or interfere with the assessment of study 
vaccines. We additionally excluded women who intended 
to travel out of the study area in the 40 days after delivery. 
Enrolment continued until the requisite number of 
laboratory-conﬁ rmed inﬂ uenza cases was detected in 
infants born to vaccinated women.
Approval for the research was obtained from the 
University of Maryland, Baltimore Institutional Review 
Board; the ethics committee of the Faculté de Médecine, 
Pharmacie et Odonto-Stomatologie of Mali; and the 
Ministry of Health of Mali. Community sensitisation was 
achieved through community leaders, health centre 
representatives and community members who attended 
community-wide meetings. All participants provided 
informed consent. If the participant was illiterate, 
consent was obtained in the presence of a literate witness 
after listening to the audiotaped version of the consent 
form in Bambara, the local language.
Randomisation and masking
Participants were randomly allocated (1:1), via a computer-
generated, centre-speciﬁ c list with alternate block sizes of 
six or 12, to receive trivalent inactivated inﬂ uenza vaccine 
(Vaxigrip, Sanoﬁ  Pasteur, Lyon, France) or quadrivalent 
meningococcal conjugate vaccine (Menactra, Sanoﬁ 
Pasteur, Lyon, France). At enrolment, consenting 
participants were assigned an identiﬁ cation number, 
which at vaccination was referenced on the randomisation 
list and the allocated treatment given. The identiﬁ cation 
numbers for ineligible participants or those who 
withdrew before vaccination were not reassigned.
Study personnel who administered study vaccines and 
were aware of treatment allocation had no contact with 
participants after vaccination and were instructed not to 
reveal the identity of the study vaccines either to 
participants or to personnel masked to treatment 
allocation. Although the syringes used to administer the 
vaccines were diﬀ erent in appearance, participants were 
instructed to look away from the vaccinator and were 
unaware of the assigned intervention.
Procedures
Quadrivalent meningococcal conjugate vaccine, rather 
than placebo, was given to controls to provide a potential 
beneﬁ t for all participants in this poor, mostly illiterate, 
vulnerable population of pregnant women. Moreover, 
that vaccine was unlikely to interfere with the primary 
outcome of the trial, yet would provide protection against 
meningococcal disease. Although disease due to 
serogroup A has largely disappeared from the region, 
other serogroups continue to cause epidemics in Mali.
The composition of trivalent inactivated inﬂ uenza 
vaccine, supplied in preﬁ lled syringes, changed during the 
trial. From September, 2011, to November, 2012, 
A/California/7/2009(H1N1[pandemic]-like), A/Perth/16/
2009(H3N2)-like, and B/Brisbane/60/2008-like (2011 
northern hemisphere formulation and then 2012 southern 
hemisphere formulation) were administered. From 
December, 2012, to April, 2013, A/California/7/2009 
(H1N1[pandemic]-like), A/Victoria/361/2011(H3N2)-like 
strain, and B/Wisconsin/1/2010-like (2012 northern 
hemisphere formulation) were administered. Quadrivalent 
meningo coccal conjugate vaccine, composed of 4 μg each 
of Neisseria meningitidis serogroup A, C, Y, and W-135 
polysaccharides conjugated to diphtheria toxoid protein, 
was supplied in single-dose vials. A single 0·5 mL dose of 
trivalent inactivated inﬂ uenza vaccine or quadrivalent 
meningococcal conjugate vaccine was injected into the 
deltoid muscle. Study vaccines were stored in secure, 
temperature-monitored refrigerators or cold rooms at 
2–8°C.
After vaccination, women were observed for 30 min. 
7 days after vaccination, ﬁ eld personnel interviewed the 
women about any local and systemic reactions. 28 days 
after vaccination, participants were clinically evaluated. 
Additional visits to evaluate safety and immunogenicity in 
women and infants were done at delivery and when the 
infant was 3 months and 6 months old. Each evaluation 
included a physical examination and blood specimen 
collection. When available, the infant birth sample was 
cord blood; otherwise, the birth sample was collected 
within 7 days after birth. To determine gestational age at 
birth, the New Ballard Score was measured at delivery or 
within 7 days after birth.19 Serious adverse events were 
recorded throughout study participation.
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Besides safety follow-up visits, from enrolment to 
when the infant reached age 6 months, ﬁ eld personnel 
undertook weekly visits to detect inﬂ uenza-like illness 
and severe acute respiratory infection. During each visit, 
the participating woman and infant (if already born) had 
their temperatures measured and were examined for 
inﬂ uenza-like illness; women were additionally examined 
for severe acute respiratory infection. When case 
deﬁ nitions for either disease were met (appendix p 5), 
nasopharyngeal and oropharyngeal swabs and a malaria 
blood smear were obtained. If inﬂ uenza was detected by 
RT-PCR, the case was deemed to be laboratory-conﬁ rmed 
inﬂ uenza. Standard-of-care treatment was oﬀ ered.
Because the primary objective was to measure the 
eﬃ  cacy of maternal immunisation for prevention of 
laboratory-conﬁ rmed inﬂ uenza in their infants younger 
than 6 months, women were withdrawn from weekly 
surveillance of inﬂ uenza-like illness following stillbirth, 
fetal death, infant death, or other events that precluded 
infant surveillance. Nevertheless, safety follow-up of 
women continued until 6 months after delivery. 
Appendix p 6 describes methods for sample collection, 
RT-PCR to detect inﬂ uenza virus, virus subtyping, and 
haemagglutination inhibition antibody measurement.
Outcomes
We assessed two coprimary objectives: vaccine eﬃ  cacy in 
infants born to women vaccinated any time prepartum 
(intention-to-treat analysis), and vaccine eﬃ  cacy in infants 
born to women vaccinated at least 14 days prepartum (per-
protocol analysis). The primary outcome was the 
occurrence of a ﬁ rst case of laboratory-conﬁ rmed inﬂ uenza 
by age 6 months. Secondary outcomes were the occurrence 
of a ﬁ rst case of laboratory-conﬁ rmed inﬂ uenza in women 
(prepartum and post partum); occurrence of a ﬁ rst case of 
febrile inﬂ uenza-like illness by age 6 months in infants; 
occurrence of a ﬁ rst case of febrile inﬂ uenza-like illness in 
women (prepartum and post partum); occurrence of local 
and systemic reactogenicity after injection, related serious 
adverse events for the entire follow-up period, and all 
pregnancy complications; levels of inﬂ uenza virus 
antibodies by haemagglutination inhibition before and 
4 weeks after vaccination, at delivery, and 3 and 6 months 
after delivery. Tertiary outcomes included the frequency of 
each inﬂ uenza virus type circulating in the study 
population, the levels of maternally derived inﬂ uenza virus 
haemagglutination inhibition antibodies present in infants 
at birth and at ages 3 and 6 months, birthweights of infants 
born at a health centre, and the occurrence of severe acute 
respiratory infection in pregnant women. Appendix p 6 
lists additional outcomes not included in the manuscript.
Statistical analysis
We calculated vaccine eﬃ  cacy with the formula:
where VE is vaccine eﬃ  cacy, h is the ratio of follow-up 
time up to age 6 months in infants born to recipients of 
quadrivalent meningococcal vaccine to the follow-up 
time in infants born to recipients of trivalent inactivated 
inﬂ uenza vaccine, and P is the proportion of all cases of 
laboratory-conﬁ rmed inﬂ uenza occurring by age 
6 months in infants whose mothers received trivalent 
inactivated inﬂ uenza vaccine. This calculation is 
equivalent to estimating vaccine eﬃ  cacy as 1–R, where 
R is the ratio of laboratory-conﬁ rmed inﬂ uenza incidence 
rates. We used the ratio of incidence rates, rather than 
the ratio of proportions of participants who had 
laboratory-conﬁ rmed inﬂ uenza to account for infants 
lost to follow-up before age 6 months. We estimated 
vaccine eﬃ  cacy in both the intention-to-treat and the per-
protocol populations. Only infants’ ﬁ rst laboratory-
conﬁ rmed inﬂ uenza episodes were counted. Follow-up 
time was time from birth to ﬁ rst case of laboratory-
conﬁ rmed inﬂ uenza, infants reaching age 6 months, or 
exiting the study. We calculated vaccine eﬃ  cacy for each 
month of age (0–5 months) and cumulative to each 
month of age.
For safety outcomes, we used Fisher’s exact tests and 
Student’s t tests to compare the proportion of participants 
who had each event per vaccine group. We did time-to-
event analysis using Cox proportional hazards regression 
with laboratory-conﬁ rmed inﬂ uenza as the outcome to 
establish whether year of vaccination or timing of 
vaccination relative to delivery had an eﬀ ect on eﬃ  cacy. 
Birthweight analysis was limited to weights that were 
either 500 g and more or 5000 g and less. We compared 
birthweight between vaccine groups both overall and 
within inﬂ uenza seasons, deﬁ ned as months with higher-
than-average rates of laboratory-conﬁ rmed illness 
(February to April, September to October).
Sample-size calculations were based on a comparison 
of the expected proportion, P, of all cases of laboratory-
conﬁ rmed inﬂ uenza that occurred by age 6 months in 
infants whose mothers received trivalent inactivated 
inﬂ uenza vaccine to the null value, P0, using exact 
binomial calculations and assuming equal total follow-
up time in each vaccine group (h=1). For the intention-
to-treat analysis, we assumed a laboratory-conﬁ rmed 
inﬂ uenza attack rate of 2·2% by age 6 months in infants 
born to recipients of quadrivalent meningococcal vaccine 
and a 55% reduction in the attack rate in infants of 
recipients of trivalent inactivated inﬂ uenza vaccine, to 
0·99%; therefore, p=0·31034 and P0=0·5. For a one-
sided α of 0·025, 77 cases of laboratory-conﬁ rmed 
inﬂ uenza were needed to ensure 90% power for the 
intention-to-treat analysis, implying a need for about 
4828 participants. Allowing for a 10% loss to follow-up, 
the sample size calculated became about 
5370 participants. For the per-protocol analysis, we 
assumed vaccine eﬃ  cacy to be 60%—ie, a laboratory-
conﬁ rmed inﬂ uenza attack rate of 0·88% by age 
6 months in infants born to recipients of trivalent 
See Online for appendix
VE = 
1–hP
(1–P)
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inactivated inﬂ uenza vaccine. To ensure 90% power to 
show a vaccine eﬃ  cacy of more than 5%, 67 cases of 
laboratory-conﬁ rmed inﬂ uenza were needed, implying a 
sample size of 4352 participants. Allowing for a 20% loss 
to follow-up, or for the mother receiving vaccine less 
than 14 days before delivery, the sample-size requirement 
became about 5440 participants.
Enrolment was closed once 77 cases of infant 
laboratory-conﬁ rmed inﬂ uenza were recorded, but 
surveillance continued until the infants reached 
6 months of age. A Data Safety Monitoring Board 
oversaw the study and reviewed data on a regular basis. 
We did analyses with Stata (version 14.0) and NCSS 
(version 10). We did power calculations with PASS 
1917 women followed up until 
 3 months post partum
179 withdrew
 38 withdrew consent
 96 moved
 1 lost to follow-up
 43 died
 1 other reason
1885 infants followed up until 
 age 3 months
2064 livebirths*
81 withdrew
 28 withdrew consent
 49 moved
 4 other reasons
1836 women followed up until 
 6 months post partum
89 withdrew
 29 withdrew consent
 48 moved
 8 died
 4 other reasons
1797 infants followed up until 
 age 6 months
38 withdrew
 25 withdrew consent
 12 moved
 1 lost to follow-up
2070 followed up until day 28
2108 received TIIV
18 withdrew
 6 withdrew consent
 12 moved
2052 followed up until delivery
104 did not receive TIIV
 44 withdrew consent
 29 were ineligible
 31 because of other reasons
135 withdrew
 38 withdrew consent
 92 moved
 2 lost to follow-up
 2 deaths
 1 other reason
1915 women followed up until 
 3 months post partum
153 withdrew
 37 withdrew consent
 75 moved
 5 lost to follow-up
 33 died
 3 other reasons
1888 infants followed up until 
 age 3 months
2041 livebirths†
90 withdrew
 27 withdrew consent
 55 moved
 1 lost to follow-up
 2 died
 6 other reasons
1825 women followed up until 
 6 months post partum
95 withdrew
 27 withdrew consent
 57 moved
 1 lost to follow-up
 4 died
 6 other reasons
1793 infants followed up until 
 age 6 months
32 withdrew
 14 withdrew consent
 11 moved
 6 lost to follow-up
2053 followed up until day 28
2085 received MCV
18 withdrew
 5 withdrew consent
 12 moved
 1 lost to follow-up
2035 followed up until delivery
128 did not receive MCV
 52 withdrew consent
 46 were ineligible
 30 because of other reasons
120 withdrew
 37 withdrew consent
 76 moved
 3 lost to follow-up
 2 died
 2 other reasons
4425 enrolled and randomly assigned
Figure 1: Trial proﬁ le
TIIV=trivalent inactivated inﬂ uenza vaccine. MCV=quadrivalent meningococcal conjugate vaccine. *1886 (91%) infants were born to women vaccinated with TIIV 14 or more days prepartum. 
†1869 (92%) infants were born to women vaccinated with MCV 14 or more days prepartum.
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(version 12). This trial is registered with ClinicalTrials.
gov, number NCT01430689.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We did this trial from Sept 12, 2011, to Jan 28, 2014. 
Between Sept 12, 2011, and April 18, 2013, we randomly 
assigned 4193 women to receive trivalent inactivated 
inﬂ uenza vaccine (n=2108) or quadrivalent meningo-
coccal vaccine (n=2085; ﬁ gure 1). Baseline characteristics 
were similar between groups (table 1). One (<1%) 
woman, who was inadvertently vaccinated twice (once 
with each vaccine), was followed up as part of her initial 
assignment group. 4087 (97%) women remained in the 
study until delivery; 3661 (87%) women were followed 
up until 6 months after delivery (ﬁ gure 1). There were 
4105 livebirths; 1797 (87%) of 2064 infants in the trivalent 
inactivated inﬂ uenza vaccine group and 1793 (88%) of 
2041 infants in the quadrivalent meningococcal vaccine 
group were followed up until age 6 months (ﬁ gure 1). 
Due to political upheaval in Mali, study personnel were 
unable to do household visits for 1 week in March, 2012, 
and 2 weeks in May, 2012.
We recorded 5279 inﬂ uenza-like illness episodes in 
2789 infants younger than 6 months, of which 131 (2%) 
episodes were laboratory-conﬁ rmed inﬂ uenza. 129 (98%) 
cases of laboratory-conﬁ rmed inﬂ uenza were ﬁ rst 
episodes (n=77 in the quadrivalent meningococcal vaccine 
TIIV group 
(n=2108)
MCV group 
(n=2085)
Age (years) 24·7 (5·9) 24·7 (6·02)
Gravidity 3·2 (2·1) 3·3 (2·1)
Parity 2·1 (2·05) 2·1 (2·03)
Gestational age at enrolment (weeks) 32·6 (3·6) 32·6 (3·7)
Available method to estimate gestational age at enrolment
Early ultrasound (<15 weeks) 326 (15%) 322 (15%)
Ultrasound after 15 weeks 667 (32%) 641 (31%)
Date of last menstrual period 136 (6%) 134 (6%)
Uterine height 979 (46%) 988 (47%)
Completed HIV testing 716 (34%) 696 (33%)
Time from vaccination to delivery (days) 53·7 (28·3) 53·3 (28·0)
Delivered at health centre 1966 (93·3%) 1988 (95·3%)
Delivery by cesarean section 128 (6%) 126 (6%)
Livebirths 2064 (98%) 2041 (98%)
Twin birth 36 (2%) 36 (2%)
TIIV=trivalent inactivated inﬂ uenza vaccine. MCV=quadrivalent meningococcal 
conjugate vaccine.
Table 1: Baseline characteristics 
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group vs n=52 in the trivalent inactivated inﬂ uenza vaccine 
group). 116 (90%) ﬁ rst episodes of laboratory-conﬁ rmed 
inﬂ uenza were in infants of women vaccinated at least 
14 days prepartum. The 77 cases needed to complete 
vaccine eﬃ  cacy analyses were reached by April 16, 2013; 
surveillance of post-partum women and their infants 
continued until infants reached age 6 months. One 
episode of laboratory-conﬁ rmed inﬂ uenza was associated 
with malaria parasitaemia.
Overall infant vaccine eﬃ  cacy was 33·1% (95% CI 
3·7–53·9) in the intention-to-treat population, and 37·3% 
(7·6–57·8) in the per-protocol population (table 2). Notably, 
cumulative vaccine eﬃ  cacy in infants in the intention-to-
treat population was 67·9% in the ﬁ rst 4 months of follow-
up, fell to 57·3% at the ﬁ fth month of surveillance, and 
dropped precipitously in the last month of follow-up, by 
which time protection was no longer evident (table 2). 
Cumulative vaccine eﬃ  cacy in infants in the per-protocol 
population was 70·2% in the ﬁ rst 4 months of follow-up 
and 60·7% at the ﬁ fth month of surveillance (table 2). 
Within the trivalent inactivated inﬂ uenza vaccine group, 
Cox regression analysis of the relative risk of laboratory-
conﬁ rmed inﬂ uenza showed that risk of inﬂ uenza 
decreased when trivalent inactivated inﬂ uenza vaccine had 
been given at least 15 days prepartum (p=0·02; appendix 
p 7). As long as the vaccine was given at least 15 days before 
delivery, no additional beneﬁ t was noted in women who 
had even longer intervals; women in neither the trivalent 
inactivated inﬂ uenza vaccine group (Cox regression 
p=0·90) nor the quadrivalent meningococcal vaccine 
group (p=0·73) had a signiﬁ cant change in rates of 
laboratory-conﬁ rmed inﬂ uenza as the time from delivery 
to vaccination increased above 14 days.
102 ﬁ rst episodes of laboratory-conﬁ rmed inﬂ uenza in 
infants were due to inﬂ uenza type A, including 41 H1N1, 
59 H3N2, and two non-subtypeable viruses, and to 
27 inﬂ uenza B viruses (table 3). In the ﬁ rst 5 months of 
life, vaccine eﬃ  cacy against inﬂ uenza A was 64·5% 
overall, and 66·6% for H1N1 and 62·9% for H3N2 
(table 3). No vaccine was eﬀ ective against inﬂ uenza 
type B in infants (table 3). In the ﬁ rst 6 months of life, no 
vaccine was eﬀ ective against inﬂ uenza-like illness 
(1% eﬃ  cacy, 95% CI –7·0 to 8·5).
During the 29 months of surveillance of infants for 
laboratory-conﬁ rmed illness, the 131 circulating inﬂ uenza 
viruses detected by RT-PCR changed over time and 
included 41 H1N1 viruses, 59 H3N2 viruses, two 
additional inﬂ uenza A viruses that could not be subtyped, 
and 29 inﬂ uenza B viruses (appendix p 8). We attempted 
to culture inﬂ uenza virus from these 131 RT-PCR-positive 
infant clinical specimens to enable more deﬁ nitive typing 
of viruses. Two contaminated samples could not be 
processed. Of the remaining 129 specimens, 65 grew 
inﬂ uenza viruses, which were typed as A/California/
7/2009(H1N1[pandemic]-like; n=32) detected from 
March, 2012, to October, 2013; A/Victoria/361/2011
(H3N2; n=11) detected from September, 2012, to October, 
2013; and B/Brisbane/03/2007 (Yamagata lineage; n=22) 
detected from November, 2012, to November, 2013. The 
H1N1 strains matched those in the trivalent inactivated 
inﬂ uenza vaccine formulations; the H3N2 strains 
matched those in the second formulation and the B 
strains were of the same lineage as that within the second 
formulation.
From Sept 12, 2011, to Jan 28, 2014, we noted 
1385 episodes of inﬂ uenza-like illness in participating 
women; 52 (4%) episodes were laboratory-conﬁ rmed 
illness. 51 (96%) cases of laboratory-conﬁ rmed illness 
were ﬁ rst episodes. One episode was associated with 
malaria parasitaemia. Appendix p 9 summarises these 
cases. There were three episodes of severe acute 
respiratory infection, all of which were inﬂ uenza 
negative. Overall vaccine eﬃ  cacy was 70·3% (95% CI 
42·2–85·8). Eﬃ  cacy against inﬂ uenza type A in women 
was 72·0% and against type B was 73·3% (table 3). 
Subtype-speciﬁ c eﬃ  cacy against H1N1 was 83·3% and 
could not be measured against H3N2 due to the few 
cases detected. Vaccine eﬃ  cacy was 76·6% (95% CI 
28·4–94·3) in pregnant women and 70·1% (28·0–89·1) 
in the post-partum period (appendix p 9). No vaccine was 
eﬀ ective against maternal inﬂ uenza-like illness (2·2% 
eﬃ  cacy, 95% CI –10·5 to 13·5).
We measured haemagglutination inhibition antibody 
titres against inﬂ uenza A/California/07/09 in 
180 mother–infant pairs (ﬁ gure 2). A subset of 43 pairs 
(plus one twin) constituted a nested case-control study in 
Women Vaccine eﬃ  cacy 
(95% CI)
Infants Vaccine eﬃ  cacy 
(95% CI)
TIIV 
group 
(n=2108)
Incidence per 
1000 person-days 
of follow-up
MCV 
group 
(n=2085)
Incidence per 
1000 person-days 
of follow-up
TIIV 
group 
(n=2064)
Incidence per 
1000 person-days 
of follow-up
MCV 
group 
(n=2041)
Incidence per 
1000 person-days 
of follow-up
Type A 7 0·03 25 0·09 72·0% (35·2 to 87·9) 17 0·06 48 0·17 64·5% (38·3 to 79·6)
H3N2 4 0·01 7 0·03 42·8% (–95·4 to 83·3) 10 0·04 27 0·10 62·9% (23·4 to 82·0)
H1N1 3 0·01 18 0·06 83·3% (43·4 to 95·1) 7 0·02 21 0·07 66·6% (21·5 to 85·8)
Type B 4 0·01 15 0·05 73·3% (19·6 to 91·1) 8 0·03 10 0·04 19·9% (–103·0 to 68·4)
TIIV=trivalent inactivated inﬂ uenza vaccine. MCV=quadrivalent meningococcal conjugate vaccine.
Table 3: Number of cases of inﬂ uenza and inﬂ uenza vaccine eﬃ  cacy against ﬁ rst episodes of laboratory-conﬁ rmed inﬂ uenza by type in women and their infants up to 5 months of age 
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which we tested samples from 11 H1N1 cases (including 
a pair of twins) and 33 birthdate-matched controls (plus 
or minus 30 days). The remaining 137 pairs included 
46 pairs with an infant with laboratory-conﬁ rmed illness, 
and 91 pairs with an infant who did not have laboratory-
conﬁ rmed illness but might have had inﬂ uenza-like 
illness; these pairs represented a convenience sample of 
participants who completed the study. By age 3 months, 
infant geometric mean titres (GMT) had decreased by 
more than 50%, although more infants in the trivalent 
inactivated inﬂ uenza vaccine group had haemag-
glutination inhibition antibody titres of 40 or more 
(ﬁ gure 2, appendix pp 10, 11). At age 6 months, 
haemagglutination inhibition antibody titres of 40 or 
more did not diﬀ er signiﬁ cantly between infants in either 
vaccine group, although maternal titres remained higher 
in the trivalent inactivated inﬂ uenza vaccine group 
(appendix p 11). Of note, GMT increased in the 
quadrivalent meningococcal vaccine group at age 
6 months, probably due to natural immunity acquired 
between ages 3 and 6 months. As haemagglutination 
inhibition antibody titres decreased with age in the 
trivalent inactivated inﬂ uenza vaccine group, eﬃ  cacy 
also decreased (ﬁ gure 2).
The most frequently reported local and systemic 
reactions were pain at the injection site and febrile 
sensation (appendix p 12). Pain at the injection site was 
more commonly reported in women given quadrivalent 
meningococcal vaccine than in those given trivalent 
inactivated inﬂ uenza vaccine (n=253 vs n=132; p<0·0001), 
although reactions were mostly mild (92%; appendix p 12). 
Rates of unrelated obstetrical and non-obstetrical serious 
adverse events in women were similar between groups 
(appendix p 13). The most commonly reported events 
were hypertensive disorders of pregnancy, which were 
equally common among both vaccine groups; 1% of 
participants in each group had pre-eclampsia (p=0·89; 
appendix p 13). No serious adverse event was related to 
study treatment. There were ﬁ ve (<1%) unrelated deaths 
among study participants (n=2 in the trivalent inactivated 
inﬂ uenza vaccine group and n=3 in the quadrivalent 
meningococcal vaccine group); two (40%) patients died 
due to obstetrical complications and three (60%) patients 
died after the 42 day period after delivery.
Although rates of serious adverse events in infants 
were similar between groups, presumed neonatal 
infection was more common in infants in the trivalent 
inactivated inﬂ uenza vaccine group than in those in the 
quadrivalent meningococcal vaccine group (n=60 vs 
n=37; p=0·02; appendix p 14). No serious adverse events 
in infants were related to maternal vaccination. 89 infants 
died: 52 (59%) infants in the trivalent inactivated 
inﬂ uenza vaccine group and 37 (41%) infants in the 
quadrivalent meningococcal vaccine group (p=0·13; 
appendix p 14); no deaths were due to laboratory-
conﬁ rmed inﬂ uenza. Appendix p 15 summarises the 
timing and causes of death.
Per-protocol analysis of the number of infants with a 
Ballard score less than 33 yielded an overall prematurity 
rate of 1·8%, which did not correlate with rates measured 
using date of last menstrual period or results of ﬁ rst-
trimester ultrasounds (appendix p 16). 358 (9%) liveborn 
infants were born at a low birthweight; there was no 
diﬀ erence in birthweight between vaccine groups 
(p=0·20). Furthermore, there was no diﬀ erence in 
birthweight among infants born during inﬂ uenza season.
Discussion
Here we report results of the largest randomised 
controlled trial so far of trivalent inactivated inﬂ uenza 
vaccine in pregnant women, which was undertaken in 
Mali, where infant and maternal mortality rates are 
among the world’s highest.14 Trivalent inactivated 
inﬂ uenza vaccine elicited robust antibody responses and 
women and their infants were signiﬁ cantly protected 
against laboratory-conﬁ rmed inﬂ uenza, corroborating 
results from Bangladesh (63% vaccine eﬃ  cacy, 95% CI 
5–85) and South Africa (48·8%, 11·6–70·4),10,11 and 
supporting WHO recommendations that pregnant 
women should be the highest priority target for inﬂ uenza 
vaccination.20 Because pregnant women and infants are 
at high risk for severe and fatal inﬂ uenza illness even in 
aﬄ  uent countries, our ﬁ ndings showing eﬃ  cacy of 
maternal immunisation in severely resource-constrained 
Mali, one of the world’s least developed countries, 
constitute encouraging new information.
Maternal immunisation with trivalent inactivated 
inﬂ uenza vaccine provided robust protection to infants 
during the ﬁ rst 4 months of life. Thereafter, as 
haemagglutination inhibition antibody titres diminished, 
eﬃ  cacy decreased and was no longer evident at month 6 of 
follow-up. These observations support the contention that 
transplacental maternal antibody protects infants against 
Figure 2: Vaccine eﬃ  cacy and HAI antibody geometric mean titres in infants, by age and maternal vaccine group 
Error bars and data in parentheses show 95% CIs.TIIV=trivalent inactivated inﬂ uenza vaccine. MCV=quadrivalent 
meningococcal conjugate v accine. HAI=hemagglutination inhibition antibodies.
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laboratory-conﬁ rmed inﬂ uenza. Haemagglutination 
inhibition antibody kinetics resembled those reported in 
Bangladesh21 and South Africa,22 and align with ﬁ ndings 
from seroepidemiological studies23,24 showing that by age 
6 months most Malian infants no longer have protective 
titres of maternally derived measles and Haemophilus 
inﬂ uenzae type b antibodies.
Inﬂ uenza vaccine was well tolerated by pregnant 
women in our study, corroborating increasing evidence 
supporting the safety of trivalent inactivated inﬂ uenza 
vaccine during pregnancy.25 The Bangladesh trial 
reported that infants born during the inﬂ uenza season to 
women who received inﬂ uenza vaccine had higher 
birthweights than did those born to women who received 
control vaccine during that period.12 In Mali and South 
Africa there was no beneﬁ cial eﬀ ect of maternal 
immunisation with trivalent inactivated inﬂ uenza 
vaccine on birthweight in infants born anytime during 
the study,11 including during inﬂ uenza season. Exclusion 
of women with high-risk pregnancies from our study and 
inclusion of women late in pregnancy might have made 
it diﬃ  cult to detect diﬀ erences in birthweight due to 
maternal disorders. Moreover, infants born to women 
who had been in the study longer had higher birthweights 
than did those vaccinated closer to delivery, further 
decreasing the likelihood of detecting a diﬀ erence 
between vaccine groups.
While demonstrating the eﬃ  cacy and safety of 
maternal inﬂ uenza immunisation, we were also able to 
address the technical and logistical feasibility of 
implementation of such a programme in Mali. The trial 
was well received by the community as the study team 
worked at local health centres alongside routine prenatal 
care (that included the administration of tetanus toxoid) 
to enrol more than 4000 women. The workﬂ ow pattern 
for administration of study vaccine paralleled that of 
tetanus toxoid administration and was well accepted by 
local providers. Nevertheless, remaining aspects, such as 
the availability of an appropriate vaccine, access to 
prenatal care, and cost, would aﬀ ect implementation of a 
maternal inﬂ uenza immunisation programme.
We noted seasonal inﬂ uenza peaks with diﬀ erent 
inﬂ uenza viruses from year to year, and these ﬂ uctuations 
aﬀ ected vaccine eﬃ  cacy. Notably, vaccinated mothers 
were signiﬁ cantly protected against inﬂ uenza B, whereas 
infants were not. The probable explanation relates to 
when diﬀ erent B-virus lineages circulated. Cases of 
type B laboratory-conﬁ rmed inﬂ uenza in infants born to 
mothers vaccinated with trivalent inactivated inﬂ uenza 
vaccine were Yamagata lineage infections, whereas 
mothers had received B/Brisbane/60/2008 (Victoria 
lineage) vaccine. By the time infants born to women 
who received Yamagata lineage-containing vaccine 
(B/Wisconsin/1/2010) were exposed to inﬂ uenza, little 
type B was circulating. This ﬁ nding shows the complexity 
of vaccine selection and supports the use of quadrivalent 
inﬂ uenza vaccines containing both type-B lineages. 
Timeliness of importation of newly formulated vaccine, 
promptness of initiation of vaccination of pregnant 
women and the types of circulating inﬂ uenza viruses in 
relation to vaccine viruses, all aﬀ ect vaccine eﬃ  cacy. If 
maternal vaccination is to succeed in Mali, infants born 
in September to October will need to be protected. 
Because northern hemisphere inﬂ uenza vaccine 
becomes available in August or September, immunisation 
will need to be implemented almost immediately upon 
vaccine importation. The second peak (February to April) 
does not present this logistical issue. An alternative 
strategy for countries with an inﬂ uenza epidemiology 
similar to Mali is to use vaccine with an extended shelf-
life throughout the year.26 This approach would allow 
immunisation of Malian pregnant women in the months 
leading up to the September to October peak before the 
newer formulation is available.
Another factor inﬂ uencing the overall eﬀ ect and 
sustainability of maternal immunisation in countries 
such as Mali is access to health-care interventions. The 
2014 Demographic and Health Survey reported that 
whereas 95·2% of pregnant women in Bamako and 
91·8% in other urban areas had at least one prenatal visit 
during their most recent pregnancy,27 this was true for 
only 69·3% of pregnant women in rural Mali. Barriers 
limiting access to health care in rural areas should be 
overcome to achieve high maternal immunisation 
coverage.
As other similarly low-resourced countries consider the 
implementation of a maternal inﬂ uenza vaccination 
programme, the cost will also aﬀ ect the feasibility. Since 
we did not observe an eﬀ ect of trivalent inactivated 
inﬂ uenza vaccine on birthweight, the cost-eﬀ ectiveness 
of implementation of the vaccine in pregnancy to prevent 
infant inﬂ uenza in Mali will hinge on prevention of 
severe illness and infant deaths. However, our study was 
not powered to measure the eﬃ  cacy of trivalent 
inactivated inﬂ uenza vaccine in the prevention of severe 
laboratory-conﬁ rmed inﬂ uenza. Furthermore, because 
we visited households of study participants weekly, and 
intervened when illnesses were encountered by treating 
and referring participants earlier than they might have 
sought care in our absence, we probably interrupted 
progression of illness in many infants. Addressing this 
gap will require a diﬀ erent trial design and a larger 
sample size.
Our study unequivocally demonstrates eﬃ  cacy of 
maternal immunisation against laboratory-conﬁ rmed 
inﬂ uenza among infants and mothers, and shows high 
acceptability and logistical feasibility, thereby paving the 
way for a larger trial to assess prevention of severe 
laboratory-conﬁ rmed inﬂ uenza leading to hospital 
admission in infants. Our ﬁ ndings support a vision that, 
in the future, developing countries might use the 
maternal immunisation platform to deliver vaccines 
to prevent respiratory syncytial virus,28 pertussis,29 
inﬂ uenza,13,26 and tetanus.30
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